- UK study offers first detailed description of COVID-19 illness in symptomatic children aged five to 17 years. Analysis reported today focuses on data from 1,734 children who tested positive for COVID-19 close to the onset of symptoms and whose symptoms were reported regularly until they were healthy again.
- Children with COVID-19 typically recovered within a week and had few symptoms (average illness lasted six days, average of three symptoms experienced), and almost all symptomatic children recovered by eight weeks (98.2%), providing reassurance about long-term outcomes from COVID-19.
- Nevertheless, some children (4.4%) experienced symptoms beyond four weeks and had an average of two persistent symptoms (typically fatigue, headache or loss of sense of smell). Long illness duration after SARS-CoV-2 infection appears less common in children than in adults.
- Symptoms were reported by a parent or carer through the ZOE COVID Study app and could not be cross-checked against health records.
- Authors highlight that all children with persistent symptoms need timely multidisciplinary care linked with education to support their recovery.
Children who develop symptoms of COVID-19 typically get better after six days and the number who experience symptoms beyond four weeks is low (4.4%, 77/1,734), a large UK study published today in The Lancet Child & Adolescent Health journal has confirmed.
The study, based on data reported through a smartphone app by parents and carers, provides the first detailed description of COVID-19 illness in symptomatic school-aged children and provides reassurance that long-term symptoms are rare.
Professor Emma Duncan, lead and senior author of the study, from King’s College London, UK, said: “It is reassuring that the number of children experiencing long-lasting symptoms of COVID-19 symptoms is low. Nevertheless, a small number of children do experience long illness with COVID-19, and our study validates the experiences of these children and their families.” [1]
Some adults experience a prolonged illness after COVID-19 (sometimes described as “long-COVID”) where symptoms persist for four weeks or longer, but it is not known whether children can develop a similar condition or how common this is. Many children infected with the SARS-CoV-2 virus do not develop symptoms, but those who do tend to have a mild illness.
In the new study, the researchers used data collected through the ZOE COVID Study smartphone app, which includes data from more than 250,000 UK children aged five to 17 years. Symptoms were reported through the app by their parents or carers (rather than assessed directly in children) and the team did not collect data regarding school attendance.
The team focused on reports collected between 1 September 2020 and 22 February 2021. Some 1,734 children developed symptoms of COVID-19 and received a positive PCR test result close to the onset of symptoms, with their symptoms reported regularly until they were healthy again. This meant the researchers could accurately attribute these children’s symptoms to COVID-19 and could assess illness duration robustly. Overall, these children were ill for an average of six days and experienced an average of three symptoms in the first week of illness, confirming that COVID-19 tends to manifest as a mild illness in children and that they usually recover quickly.
Most children recovered within four weeks, with a minority experiencing symptoms after a month (4.4%, 77/1,734). Typically, they had only two symptoms remaining after four weeks. The commonest symptom experienced by children with long illness duration was fatigue. 84% (65/77) of children were reported with fatigue at some point in their illness, and this was the most persistent symptom. Headache and loss of sense of smell were also common, (each symptom experienced by 77.9% (60/79) of children at some stage over the course of their illness). However, headache was more common early in illness whilst loss of sense of smell tended to occur later and to persist longer.
Of the 1,379 children who developed symptoms at least two months before the end of the study period (on or before 29 December 2020), fewer than 2% experienced symptoms for longer than eight weeks (1.8%, 25/1,379).
Older children were typically ill for longer than primary school aged children (average illness duration 7 days in children aged 12 to 17 years vs 5 days in children aged 5 to 11 years). Older children were also more likely to have symptoms after four weeks than younger children (5.1% [59/1,146] children aged 12 to 17 years vs 3.1% [18/588] aged 5 to 11 years), but there was no difference in the numbers of children who still had symptoms after eight weeks (2% [19/934] aged 12 to 17 years vs 1.3% [6/445] aged 5 to 11 years).
Dr Erika Molteni, first author of the study, from King’s College London, said: “We found that nearly a quarter of symptomatic children testing positive for SARS-CoV-2 during the UK’s second wave did not report core symptoms, suggesting the UK testing policy needs reconsideration.” [1]
Importantly, the researchers also assessed the children who tested negative for COVID-19 who may have had other childhood illnesses, such as colds and flu. To do this, they randomly selected a group of age-matched and gender-matched children with symptoms reported through the app who were tested at the same time as the positive children.
Children with COVID-19 were ill for longer compared to children with other illnesses who tested negative for COVID-19 (an average of 6 days’ illness with COVID-19 vs 3 days with other illnesses) and were more likely to be ill for more than four weeks (4.4% [77/1,734] with COVID-19 vs 0.9% [15/1,734] for children with other illnesses). However, at four weeks, the small number of children with other illnesses tended to have more symptoms than those who were ill with COVID-19 (average 5 symptoms in COVID-negative group vs 2 symptoms in COVID-positive group).
Dr Michael Absoud, a senior author of the study and Consultant & Senior Lecturer at King's College London, said: “Our data highlight that other illnesses, such as colds and flu, can also have prolonged symptoms in children and it is important to consider this when planning for paediatric health services during the pandemic and beyond. This will be particularly important given that the prevalence of these illnesses is likely to increase as physical distancing measures implemented to prevent the spread of COVID-19 are relaxed. All children who have persistent symptoms – from any illness – need timely multidisciplinary support linked with education, to enable them to find their individual pathway to recovery.” [1]
The authors note some limitations to their findings. They could not cross-check the symptoms reported by parents and carers with health records (noting that most children were managed in the community), and there may be inconsistencies in the way people interpret symptoms on behalf of their children. Crucially, only children who had an adult who was participating in the COVID Symptom Study were able to participate, which may bias participation towards certain demographic groups.
They also note that their findings on the number of children experiencing prolonged symptoms are lower than the most recent figures from the UK Government’s Office of National Statistics (ONS) [2]. They say this discrepancy may arise because of differences in way the two studies define the end of COVID-19 illness. The current study also allowed for children to have relapsing and remitting symptoms (allowing for periods of a up to a week of being completely healthy). When the ONS used similar cut-offs, the differences between the figures reported here and the ONS data were quite similar. Additionally, ONS estimates are based on data collected monthly, which relies on individuals remembering details of when symptoms were experienced, whereas the COVID Symptom Study collects data in real time.
Professor Emma Duncan added: “We hope our results will be useful and timely for doctors, parents, and schools caring for these children - and of course the affected children themselves.” [1]
NOTES TO EDITORS
The study was carried out by researchers from King’s College London, University College London, Newcastle University, London School of Hygiene & Tropical Medicine, St Thomas’ Hospital, King’s Health Partners, and Zoe Limited. It was funded by Zoe Limited, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation and Alzheimer’s Society.
[1] Quote direct from author and cannot be found in the text of the Article.
[2] The Office of National Statistics: “Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021” [Accessed 19 July 2021]
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office pressoffice@lancet.com
For interviews with the Article authors, Professors Emma Duncan and Michael Absoud, please contact Rebecca Lewis, Senior News and Campaigns Officer, Kings College London E) Rebecca.s.lewis@kcl.ac.uk T) +44 7961 046 72
NOTE: THE ABOVE LINK IS FOR JOURNALISTS ONLY; IF YOU WISH TO PROVIDE A LINK FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS: www.thelancet.com/journals/lanchi/article/PIISS2352-4642(21)00198-X/fulltext
Contact The Lancet press office:
LONDON
Emily Head, Media Relations Manager
Tel: +44 (0) 7920 530997
emily.head@lancet.com
USA
Johanna Harvey, Media and Communications Manager, North America
Tel: +1 267-515-1767
johanna.harvey@lancet.com
OUTSIDE OF UK HOURS
Tel: +44 (0) 207 424 4249